Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
14 janv. 2023 04h00 HE
|
Arcutis Biotherapeutics, Inc.
During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 janv. 2023 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
19 déc. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Regulatory submission for the expanded indication is supported by data from two recently completed 4-week Maximal Usage Systemic Exposure (MUSE) studies in children ages 2 to 11 years with plaque...
Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
12 déc. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Study met the primary endpoint and key secondary endpoints, consistent with positive topline results from the INTEGUMENT-1 trial released in NovemberFor the primary endpoint, 28.9% of individuals...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 déc. 2022 16h01 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
05 déc. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver...
Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
28 nov. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Newly published phase 2b trial data show those treated with roflumilast cream had significantly greater improvements in itch compared to those treated with vehicle by Week 2 as assessed by the Worst...
Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report
21 nov. 2022 09h15 HE
|
Arcutis Biotherapeutics, Inc.
Report highlights efforts to advance diversity and inclusion, access to medicine, sustainable business practices, and governance WESTLAKE VILLAGE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Arcutis...
Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
17 nov. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
ZORYVE is now on formulary for one of the top pharmacy benefit managers serving commercially insured patients, effective November 18, 2022ZORYVE is a once-daily non-steroidal cream and the first and...
CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
15 nov. 2022 11h10 HE
|
Arcutis Biotherapeutics, Inc.
Study met the primary endpoint and all secondary endpointsFor the primary endpoint, 32.0% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success...